90 likes | 222 Views
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. www.shift-study.com. Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.
E N D
Systolic Heart failure treatment withthe Ifinhibitor ivabradine Trial Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.
Outcomes in placebo patients grouped according to tertiles of systolic blood pressure and resting heart rate Rate of primary end point (cardiovascular mortality or hospitalization for worsening heart failure), % Heart rate at baseline ≥81 bpm 74 to <81 bpm <74 bpm <115 mm Hg 115 to <130 mm Hg ≥130 mm Hg Systolic blood pressure at baseline P=0.0058 for difference between the groups www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.
Outcomes in placebo patients according to tertiles of baseline systolic blood pressure Rate of primary end point (cardiovascular mortality or hospitalization for worsening heart failure), % P=0.0003 for difference between the groups <115 mm Hg 115 to <130 mm Hg ≥130 mm Hg Time (years) Numbers at risk www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.
Effect of ivabradine on primary outcomes (CV death or HF hospitalization) according to systolic blood pressure level Baseline systolic blood pressure <115 mm Hg HR 0.84 (95% CI, 0.72 to 0.98), P=0.022 Placebo Incidence of primary end point (%) Ivabradine Time (years) Numbers at risk www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.
Effect of ivabradine on primary outcomes (CV death or HF hospitalization) according to systolic blood pressure level Baseline systolic blood pressure 115 to <130 mm Hg HR 0.86 (95% CI, 0.72 to 1.03), P=0.099 Incidence of primary end point (%) Placebo Ivabradine Time (years) Numbers at risk www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.
Effect of ivabradine on primary outcomes (CV death or HF hospitalization) according to systolic blood pressure level Baseline systolic blood pressure ≥130 mm Hg HR 0.77 (95% CI, 0.66 to 0.92), P=0.003 Incidence of primary end point (%) Placebo Ivabradine Time (years) Numbers at risk www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.
Effect of ivabradine on primary outcomes (CV death or HF hospitalization) according to systolic blood pressure level Rate of primary end point (cardiovascular mortality or hospitalization for worsening heart failure), % P for interaction =0.68 Baseline SBP <115 mm Hg Baseline SBP 115 to <130 mm Hg Baseline SBP≥130 mm Hg HR 0.84 (95% CI, 0.72 to 0.98), P=0.022 HR 0.86 (95% CI, 0.72 to 1.03), P=0.099 HR 0.77 (95% CI, 0.66 to 0.92), P=0.003 Placebo Placebo Placebo Ivabradine Ivabradine Ivabradine Time (years) Time (years) Time (years) www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.
Effect of ivabradine on other outcomes according to baseline systolic blood pressure www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.
Adverse event leading to withdrawal according to systolic blood pressure level www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.